The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are delivering impressive returns.

Within the group of top-performing health care ETFs are genomics funds. Entering 2020, the genomics industry was already on a compelling trajectory with declining gene sequencing costs bolstering the long-term case for related investments.

The race for a coronavirus solution is merely icing on the cake for some of the funds in this category, particularly those that Moderna allocations prior to that name ascending to story stock status.

There are multiple genomics ETFs to consider. Here’s a trio of standouts from the category…CLICK for complete article